Navigation Links
Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR
Date:9/12/2013

ilure of product development programs; (5) actions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates in development; and (8) integration activities with acquired companies.

The forward-looking statements contained in this press release speak only as of the date of this press release, and Takeda undertakes no obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If Takeda does update or correct one or more of these statements, investors and others should not conclude that Takeda will make additional updates or corrections.

Contacts:
Takeda Pharmaceuticals U.S.A., Inc.
Kara Hoeger
+1-224-554-1277
kara.hoeger@takeda.com

Takeda Pharmaceutical Company Limited
Corporate Communications Dept. (PR/IR)
+81-3-3278-2083

Arbor Pharmaceuticals, LLC
Brian Adams
+1-404-496-5915
badams@arborpharma.com


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
2. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
3. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
4. Takeda Launches New Subsidiary in Peru
5. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
6. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
7. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
8. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
9. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
10. Takeda to Acquire Inviragen, Inc.
11. Takeda Responds to Verdict in Diabetes Drug Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  Desert Valley Medical Center, named a ... is the first U.S. hospital to deploy the wireless Leaf ... help reduce the duration of labor and risk of caesarian ... the risk of caesarean birth is reduced in mothers who ... mothers in labor are given epidurals and tend to lie ...
(Date:5/5/2015)... , May 05, 2015 Research and Markets ... the "Home Healthcare Global Market - Forecast to ... home healthcare market is expected to reach more than ... The home healthcare equipment market is expected ... healthcare services market. Home healthcare is gaining a tremendous ...
(Date:5/5/2015)... -- Lymphatic pump treatment (LPT) shows promise in managing ... new study published in The Journal of the ... LPT on infected rats three times a day followed ... treat pneumonia. After 96 hours, over 60 percent of ... percent of rats who received levofloxacin alone. ...
Breaking Medicine Technology:Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 2Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 3Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 4Global Home Healthcare Global Market 2015 - Forecast to 2020 for the $300 Billion Market 2Lymphatic Pump Treatment Enhances Antibiotic Effectiveness for Treating Pneumonia 2
... of the technology world moves to Basking Ridge, NJ when ... Trade-Investment Promotion Agency (KOTRA), kicks off later this month. The ... together companies seeking the most innovative and creative technology in ... at 8:30AM EDT (US & Canada) at the Dolce Hotels ...
... DURHAM, N.C., Oct. 18 Argos Therapeutics ... president and chief executive officer, will present an overview of ... EDT on Oct. 21 at the inaugural Cancer Immunotherapy Conference ... Ph.D ., the company,s chief scientific officer and vice president ...
Cached Medicine Technology:Top U.S. and Korean Companies to Converge at 2010 Global Partnering Day 2Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference 2
(Date:5/5/2015)... Fla. (PRWEB) May 05, 2015 Baptist ... the Commission on Cancer (CoC) of the American College ... cancer program must meet more than 30 Commission on ... through a survey process, and maintain levels of excellence ... , When patients choose to seek care locally at ...
(Date:5/5/2015)... Atlanta, Georgia (PRWEB) May 05, 2015 ... Software of Victoria BC announced the Skedans Sensor ... The platform, for mobile and web app developers, provides ... from airborne and mobile sensors. , The Skedans Sensor ... at the intersection of the Internet of Things, Web ...
(Date:5/5/2015)... May 05, 2015 MAP Health Management, ... revenue cycle management for addiction treatment facilities, announced today ... President of Business Development. Mr. Mooney, who has more ... field, will be responsible for developing new strategic partnerships ... MAP’s core products and new initiatives. , Prior to ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Okyanos, the ... Lifestyle Report today. The study was conducted to determine ... as osteoarthritis and sports-related injuries have had ... stiffness was the most prevalent symptom reported at 73%, ... as walking, standing and bending over. Over half of ...
(Date:5/5/2015)... On April 8th, 2015, at the ... Recovery sponsored Durkin Entertainment’s “RockNRolla” EcoLuxe Lounge, a daylong ... sustainable product placement in TV and film. , ... of ecologically sound and socially conscious products and services, ... that makes appearances at various awards ceremonies and festivals ...
Breaking Medicine News(10 mins):Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:Jimmy Mooney, an Addiction Treatment Veteran, Named Vice President of Business Development at MAP Health Management, LLC 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2
... against RSV, research shows , THURSDAY, Dec. 24 (HealthDay News) ... the ability to prevent infection with respiratory syncytial virus (RSV), ... can also be dangerous for adults with chronic lung diseases ... known as POPG, seems to help the lungs do a ...
... Dec. 24 Congressman Chaka Fattah (D-PA) releases the following ... legislation: , "Senate Democrats deserve our thanks and congratulations ... do, but I am confident that the House and the ... new year we will be sending President Obama a final ...
... improving legislation in conference committee , WASHINGTON, Jan. 24 ... this morning,s passage of the Patient Protection and Affordable Care ... and Senate to begin merging their respective bills and enact ... morning the Senate brought us closer to meaningful health care ...
... , WASHINGTON, Dec. 24 Today, The U.S. Conference of Mayors ... to provide health care for millions of the uninsured. In ... Senate passed the Patient Protection and Affordable Care Act. ... on legislation on Christmas Eve. It is appropriate the ...
... AARP Idaho Says Now Is the Time for State Congressional ... 24 Before the sun was up in Idaho ... costs received a glimmer of hope from Washington, D.C. With ... the Idaho congressional delegation can play a key role in making ...
... cells, study finds , THURSDAY, Dec. 24 (HealthDay News) -- ... cold and heal wounds, but the antioxidant might have another ... cells, new research suggests. , The findings, published online ... add to previous research that showed how adult cells can ...
Cached Medicine News:Health News:Discovery in Lungs May Lead to Treatment for Respiratory Virus 2Health News:AARP Thanks Senate for Passing Health Care Reform 2Health News:Health Care Reform Moves One Step Closer to Bringing Relief to Idaho Families 2
Intended for the quantitative determination of urea nitrogen in serum. Reaction: kinetic. Wavelength: 340 nm. Linearity: 150 mg/dL (53.4 mmol/L urea) at 37C....
For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
... spectrophotometer designed specifically to run 24 hours ... rugged hardware, proven optical performance and a ... traditional spectrophotometry to obtain results quickly, accurately ... up to eight, 1 cm Biocell cuvettes ...
Medicine Products: